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Abstract
Background: Bronchiolitis is an acute lower respiratory infection which predominantly affects young children. Treatment
for bronchiolitis is limited to supportive therapy. Nasal oxygen therapy is part of routine care, and delivery now incorporates
varying levels of non-invasive continuous positive airway pressure and/or high-flow nasal cannula oxygen therapy. Despite
wide clinical use, there remains a lack of evidence on the comparative effectiveness and safety of these interventions.
Furthermore, research in this field is hampered by the use of multiple outcome measures in current clinical trials.
Methods/design: This mixed methods study includes a systematic review of outcome measures, telephone interviews with
parents, focus group workshops and a Delphi survey with healthcare professionals and parents. These methods will be used
to identify and prioritise outcomes for inclusion in a core outcome set and to explore issues pertinent to the design of a
future randomised controlled trial comparing different modes of oxygen therapy for bronchiolitis. UK hospitals will also be
contacted and asked to complete a survey to provide an overview of current practice to enable assessment of capability
and capacity to run a future clinical trial.
Discussion: This study will facilitate the design of a future clinical trial of non-invasive ventilation in children
with bronchiolitis which is acceptable to important stakeholders. Furthermore, core outcome set development
will improve standardisation, measurement and reporting of clinically important outcomes in bronchiolitis.
Trial registration: ISRCTN Registry, ISRCTN75766048. Registered on 18 December 2017. This study was
retrospectively registered in the ISRCTN Registry and on the Core Outcome Measures in Effectiveness Trials
(COMET) Initiative database (15 September 2017).
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Background
Bronchiolitis is an acute viral lower respiratory tract infec-
tion which predominantly affects children up to two years
of age. Respiratory syncytial virus (RSV) is the most com-
mon cause of bronchiolitis [1]. Symptoms comprise a co-
ryzal prodrome lasting approximately three days,
persistent cough, increased respiratory rate, chest reces-
sion and wheeze or crackles on auscultation [2]. Most
children with bronchiolitis have mild symptoms and can
be managed at home [3]. However, up to 3% of all infants
are hospitalised with this condition, most commonly be-
tween 1 and 6 months of age [4, 5]. Between 2004 and
2011, admissions for bronchiolitis in the UK rose by 60%
[6]. The median duration for hospitalisation with this condi-
tion varies substantially across the UK and Europe [7], likely
reflecting variations in clinical practice and socio-economic
conditions [4, 8]. A significant proportion of infants present
to healthcare services with severe disease or deteriorate
whilst in hospital, requiring intensive care [9, 10].
Treatment for bronchiolitis is principally supportive, com-
prising oxygen and fluids/nutritional support [2]. A number
of treatment interventions have been assessed in clinical tri-
als and systematic reviews, including antibiotics, bronchodi-
lators, chest physiotherapy, epinephrine, leukotriene
inhibitors, glucocorticoids, heliox, hypertonic saline, im-
munoglobulin, inhaled corticosteroids, oxygen therapy, re-
combinant deoxyribonuclease (rhDNase), steam inhalation
and humidity, exogenous surfactant (in mechanically venti-
lated infants), nasal continuous positive airway pressure
(nCPAP) and high-flow nasal cannula (HFNC) [11–24]. Oxy-
gen therapy and the use of oximetry is the only intervention
that has had a major impact on survival over the last 40 years,
contributing to a reduction in mortality rates from around
20% to < 1% [1, 25]. Over the last two decades, giving oxygen
nasally and non-invasively with varying levels of positive air-
way pressure or flow has become an important part of the
routine clinical management of hospitalised children with
bronchiolitis, particularly those with severe disease [26–28].
This is done in one of two ways, with nCPAP or HFNC [29].
Nasal continuous positive airway pressure (nCPAP)
This method works by delivering an air/oxygen mixture
at a preset distending airway pressure, thereby widening
peripheral airways and allowing deflation of over-dis-
tended lungs [30]. It is widely used to treat respiratory
distress and reduce the need for intubation and invasive
ventilation in infants with worsening bronchiolitis, par-
ticularly in critical care settings [31]. In spite of its wide-
spread use, there is little good-quality research on the
efficacy of nCPAP or optimum thresholds for its initi-
ation. Observational studies provide some indication
that nCPAP may provide an alternative to mechanical
ventilation, based on improvement in physiological
parameters and temporal trends showing reduction in
invasive ventilation in bronchiolitis [27–29]. A Cochrane
systematic review published in January 2015 [21] found
only two small, randomised controlled trials (RCTs) [32, 33]
that showed improvement in their respective primary out-
comes: partial pressure of carbon dioxide (PCO2) reduction;
respiratory distress score. However, both RCTs had major
methodological flaws, including small sample sizes, short
protocol durations and the use of surrogate endpoints of
questionable relevance either clinically or to patients/families.
The Cochrane ‘bottom line’ was that the effect of nCPAP in
children with acute bronchiolitis is uncertain and larger trials
with adequate power are needed [21].
High-flow nasal cannula (HFNC)
HFNC is a recent introduction to clinical practice. The pre-
cise mechanism of action is unclear but thought to support
effort of breathing through providing a distending pressure
[29]. Furthermore, it allows humidified warm high-flow air/
oxygen blends to be delivered using specific cannulas and
has potential for use in different settings, including critical
care, high-dependency units, general wards and emergency
departments (EDs) [30]. Proof-of-concept studies focusing
on physiologic outcomes have shown promise, and obser-
vational evidence also suggests clinical benefit from the use
of HFNC in bronchiolitis [34–36]. However, a Cochrane re-
view published in 2014 found only one pilot clinical trial of
sufficient quality for inclusion and concluded that further
research needed to be undertaken [37]. More recently, the
first published RCT comparing HFNC with low-flow oxy-
gen (2 L/min nasal cannula wall oxygen) in inpatients with
bronchiolitis suggested a benefit in reducing treatment fail-
ure, despite no change in duration of oxygen therapy [38].
nCPAP vs HFNC
Compared to nCPAP, it is believed that HFNC is better toler-
ated and more straightforward to use, may reduce skin and
nasal trauma and is associated with reduced costs [39–42].
Whilst further studies are currently underway to clarify the
benefits and risks of HFNC compared to low-flow oxygen,
the first head-to-head comparisons between nCPAP and
HFNC have been recently published [39, 43]. The TRA-
MONTANE multi-centred RCT, conducted in paediatric in-
tensive care units in France, suggested that respiratory
support provision by nCPAP may be more efficient than that
by HFNC [39]. However, many gaps in evidence remain re-
garding the comparative efficacy and safety of both treat-
ments for different levels of bronchiolitis severity. Future
RCTs should consider feasibility across settings, thresholds
of use, and adequate outcome selection.
Outcome selection for use in clinical trials of bronchiolitis
Selection of appropriate primary and secondary out-
comes is essential for study design, as ultimately any
study is only as credible as its endpoints [44]. To be
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useful, clinical trials that evaluate benefits and harms of
interventions must select outcomes of relevance to
stakeholders and measure them using instruments with
adequate measurement properties [45]. Inconsistent se-
lection, measurement and reporting of outcomes in clin-
ical trials raise three problems [46]. First, outcomes may
not consistently reflect endpoints that are meaningful
for all stakeholders, particularly parents and caregivers
or healthcare professionals (HCPs) in different settings.
Second, inconsistency in measurement domains and in-
struments is a barrier to compare, contrast and combine
trial findings, which will inevitably affect their interpret-
ation and future uptake. Third, if researchers have mea-
sured a particular outcome in a variety of ways, outcome
reporting bias may ensue.
These issues could be addressed with the development
and application of an agreed standardised set of outcomes
(a ‘core outcome set’) pertinent to all stakeholders, espe-
cially patients/carers and HCPs [46, 47]. To develop a core
outcome set (COS), one must distinguish between potential
domains (’what to measure’) and measurement instruments
(’how to measure’) and define the process to identify them
and to reach consensus on which to include in a COS.
Considerable methodological evidence has accumulated in
this field, and guidance is available to support the develop-
ment, implementation, evaluation and updating of a COS
[48]. The recent handbook by the COMET Initiative rec-
ommends a four-step process to develop a COS [48].
One of the key limitations identified by most systematic
reviews of treatments in acute viral bronchiolitis across
different settings has been the heterogeneity in the selec-
tion of outcomes and measurements reported in clinical
trials [49]. However, the extent of this heterogeneity is un-
known. A recent nationwide online survey conducted in
Portugal identified outcomes of relevance to paediatricians
and general practitioners [50] but did not seek the per-
spectives of parents or other stakeholders, and no consen-
sus procedure was undertaken. No COS has been
previously developed for this condition.
Methods/design
Aims and objectives
The long-term aim of the NOVEMBR study is to find
out how to best provide respiratory support to children
with bronchiolitis when they are admitted to hospital
(see Additional file 1).
The specific aims of the NOVEMBR feasibility study
are to:
1. Develop a COS for use in future clinical trials in
bronchiolitis
2. Explore issues critical to the design of an RCT of
non-invasive ventilation in children with
bronchiolitis
3. Comprehensively assess current UK practice as
regards bronchiolitis management, potential trial
capability and acceptability
Setting
This multi-centre study will be undertaken at seven
UK National Health Service (NHS) hospitals (district
general hospitals [n = 4] and paediatric tertiary centres
[n = 3]).
Stakeholder involvement
An important aspect of the NOVEMBR study is consult-
ation with and involvement of key stakeholders (parents/
carers and HCPs) at all stages. The purpose of involving
these parties is to ensure capture of their unique experi-
ences and opinions. This knowledge will inform the de-
sign of a future RCT and COS development in the
broadest sense.
Two parents were consulted in the initial stages of the
design of the study. They discussed their experiences of
having a child admitted to hospital with bronchiolitis
and the treatment received. Discussion with these par-
ents highlighted a number of fundamental issues for ex-
ploration within the proposed study, including:
 Parental capacity to provide informed consent in the
emergency setting
 Acceptability of deferred consent
 Route and time from admission to diagnosis and
intervention (e.g. starting nCPAP or HFNC)
 Infant’s intolerance of nCPAP
 Parental priorities in consent decision-making
 Concerns about the long-term impact of
bronchiolitis
 Willingness to participate in any RCT, including
follow-up stages
Parent participation in the study was discussed. Both
parents said they thought parents would appreciate the
opportunity to meet other parents with similar experi-
ences and discuss the RCT in a workshop event. Fur-
thermore, both parents recommended that workshop
events and interviews should be incorporated into the
NOVEMBR feasibility study protocol.
Study management and oversight
The study will be overseen by a study management
group (SMG) and a Study Steering Committee (SSC). A
clinical trial manager will be appointed. The SMG will
meet monthly and oversee day-to-day management and
overall conduct and progress of the study including any
protocol amendments. The SMG will include all re-
search study team members. The SSC will meet at
6-monthly intervals and will include an independent
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Chairperson and two other independent expert members
who can provide specific advice on methodology, nurs-
ing, bronchiolitis and critical care. There will also be
representatives from the SMG. The purpose of the SSC
will be to provide support and guidance on the conduct
of the study and ensure that the study complies with
good clinical practice (GCP) principles, relevant regula-
tions and adherence to study protocol. Two parents will
be invited to participate in the study management and
oversight process. The SSC will report to the funding
body.
Study design
This mixed methods study will include a systematic re-
view, focus group workshops (parents/carers and HCPs),
telephone/Skype interviews (parents/carers), a Delphi
survey (parents/carers and HCPs), a national survey of
practice (lead paediatricians) and a consensus meeting
(parents/carers and HCPs). These methods will be
undertaken to identify and prioritise important out-
comes for inclusion in a COS and to explore important
issues which will inform the design of a future RCT. In
addition, UK hospitals will be contacted and asked to
complete a survey to provide an overview of current
practice to enable assessment of capability and capacity
to run a future clinical trial. Figure 1 illustrates the
NOVEMBR study flow diagram.
Core outcome set (COS) scope and development
The scope of the COS will principally be developed for
use in RCTs of interventions (pharmacological or
non-pharmacological) for children with a clinical diag-
nosis of bronchiolitis in a hospital setting. Methods rec-
ommended by Core Outcome Measures in Effectiveness
Trials (COMET) and COnsensus-based Standards for
the selection of health Measurement INstruments (COS-
MIN) will be used to guide the development of the
bronchiolitis COS [48, 51, 52]. A list of outcomes will
initially be created from the systematic review and stake-
holder consultation (workshops and interviews). Similar
outcomes will be collapsed and merged. A conceptual
outcomes framework has been developed based on pre-
vious exploratory work1 (unpublished data) [48, 53]. The
outcome domains and sub-domains for the framework
will be defined a priori. We will categorise the list of
outcomes under relevant domains and sub-domains in
the outcome framework prior to inclusion in the Delphi
survey. Obtaining consensus for importance for identi-
fied outcomes will be an iterative process. A variety of
consensus methods will be used within the stakeholder
workshops, interviews and Delphi survey, culminating in
an end-of-study consensus meeting.
Systematic review of outcome measures
The following methods for systematic review of outcome
measures have been adapted for use from the mOMEnt
study [54, 55].
Studies will be eligible for inclusion if they meet the
following inclusion criteria:
1. Study design: RCTs will be included, regardless of
specific RCT design.
2. Participants: Infants and children up to 24 months
of age with a clinical diagnosis of bronchiolitis in
any setting (outpatient, inpatient, paediatric critical
care) will be eligible. To accommodate different
perspectives on bronchiolitis definition, a pragmatic
approach will be used as defined by RCT authors. A
priori studies with participants known to have had
recurrent wheezing will not be excluded.
3. Interventions: All interventions (pharmacological,
medical devices or other) at the patient level will be
considered, including but not limited to HFNC,
nCPAP, nebulised hypertonic saline,
bronchodilators, corticosteroids, surfactant therapy,
antibiotics, deoxyribonuclease, steam inhalation or
humidified oxygen, heliox, leukotriene inhibitors,
epinephrine, glucocorticoids, chest physiotherapy,
suctioning, inhaled corticosteroids, oxygen
saturation, fluids and nutritional support.
Fig. 1 NOVEMBR study flow diagram
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Studies will be excluded if they:
1. Do not recruit exclusively participants with
bronchiolitis
2. Include participants diagnosed with bronchiolitis
obliterans
3. Evaluate the effectiveness of monoclonal antibody
(palivizumab) for the prevention of bronchiolitis
4. Test interventions implemented at the population
level
5. Are not published in one of the following
languages: Dutch, English, French, German, Italian,
Portuguese, Spanish and Turkish.
The following electronic databases will be searched to
identify relevant RCTs: OvidSP MEDLINE (1946–2015),
Central Register of Clinical Trials (CENTRAL; the
Cochrane Library), OvidSP Embase (1974–2015), Scopus
(1982–2015). See Additional file 2.
Titles and abstracts will be screened independently by
two authors (CvM and RF), and full publication will be
obtained for potentially eligible studies. Two researchers
(CvM and RF) will independently assess eligibility of the
full reports against the inclusion criteria. Disagreements
will be resolved through discussion. A data extraction
form will be developed and pilot tested for use. Data ex-
tracted from eligible studies will include author details;
reference; country; setting; number of centres; study dur-
ation; population; sample size; study inclusion/exclusion
criteria; intervention(s); length of follow-up; and re-
ported outcomes, including any primary/secondary out-
comes, definition and when and how they are measured.
The data extraction forms will be compared for agree-
ment. Disagreements will be resolved through discus-
sion. If the published data are unclear or unavailable, the
study authors will be contacted for further clarification.
The quality of describing and reporting the outcomes
will be assessed within each study by considering the fol-
lowing questions [54, 55]:
1. Is the primary outcome clearly stated?
2. Is the primary outcome clearly defined so that
another researcher would be able to reproduce its
measurement?
3. Are the secondary outcomes clearly stated?
4. Are the secondary outcomes clearly defined?
5. Do the authors explain the use of the outcomes
they have selected?
6. Are methods used to enhance the quality of
outcome measurement (for example, repeated
measurement, training) if appropriate?
For this study there will be no statistical synthesis of
outcome data of included studies. The methodological
quality or risk of bias of the included studies will not be
evaluated. The extracted data will be entered into a
Microsoft Excel database to aid tabulation and data ana-
lysis. For analysis purposes, the data will be initially tab-
ulated so that each study is listed with the outcomes
measured. Outcomes will be grouped under appropriate
outcome domains by one author (CvM). These group-
ings will be checked by co-authors. The outcome do-
mains will be determined based on a predefined
conceptual framework that will be developed based on
previous exploratory work and adjusted as needed fol-
lowing a review of the extracted outcomes by the au-
thors (Footnote 1: unpublished data) [48]. The outcome
domains and included outcomes will be reviewed by the
SSC to assess suitability of domain name and grouping
of outcomes. Within each domain, we will be able to
evaluate how many different outcomes have been used
to reflect that domain, the frequency of selection for
each individual outcome and the times at which they
were measured. Tables will be created describing every
parameter related to the outcomes used and will refer to
which trials reported them. Stratification will be done by
intervention and setting in which the trial was con-
ducted, and primary and secondary outcomes will be
identified. A narrative synthesis summarising the find-
ings will be undertaken.
Focus group workshops and telephone/Skype interviews
Focus group workshops and telephone/Skype interviews
with stakeholders (parents/carers and HCPs) will be
used to identify outcomes and explore perceptions on
the design of a future trial of non-invasive ventilation in
children with bronchiolitis. This will include the use of
consensus methods to prioritise and obtain agreement
on specific aspects of the trial design including primary
and secondary outcome measures. Stakeholder accept-
ability of a future trial will also be determined. Parents/
carers and HCPs will be eligible if they meet the follow-
ing criteria:
1. Parents/carers of a hospitalised child (including ED
attenders), aged 0–24 months, with a clinical
diagnosis of bronchiolitis defined as per National
Institute for Health and Care Excellence (NICE)
Bronchiolitis Guidelines (2015) [56].
2. HCPs (doctors, nurses, physiotherapists) who have
at least 6 months’ experience in managing children
diagnosed with bronchiolitis in the following
clinical locations: ED, acute assessment unit,
medical ward and critical care unit.
Parents/carers will be excluded from participation if
they do not speak English or if their child had died dur-
ing hospital admission.
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A purposive sampling framework will be used to re-
cruit up to 35 parents/carers (workshops (n ≤ 20); inter-
views (n ≤ 15)) and approximately 80 HCP stakeholders.
To ensure maximum variation, stakeholders will be
stratified by specific characteristics. Parents/carers will
be stratified by their child’s gender, severity of illness and
age, whilst HCPs will be stratified by profession type,
grade and clinical area. The sample will be reviewed as
recruitment is in progress and will be amended as neces-
sary to avoid over-recruitment of stakeholders with simi-
lar characteristics.
A member of the local research team will disseminate
written and verbal information about the study to con-
sultant paediatricians and other members of the direct
clinical care teams either through email, individual
face-to-face meetings or at appropriate meetings. To
maximise recruitment, the direct clinical care team will
be asked to identify eligible parents/carers either pro-
spectively during their child’s hospital visit/admission or
retrospectively for those children who have been re-
cently discharged home. For retrospective recruitment, a
letter will be sent to eligible parents/carers via the clin-
ical care team inviting the parent/carer to contact the re-
search team to register interest.
Parent/carer focus group workshop To facilitate en-
gagement with parents/carers, the workshop will be held
at a family-friendly venue with facilities to provide a
stimulating environment for children who attend with
their parents/carers. A crèche facility will be available
with qualified nursery staff. All travel expenses will be
reimbursed, and parents/carers will be presented with a
gift voucher.
Recruitment for the workshop will take place at three
study sites in North West England located close to the
workshop venue. Parents/carers will be provided with
both written and verbal study information. A week prior
to the workshop, parents/carers will be sent a copy of
the workshop agenda and the NOVEMBR trial partici-
pant information sheet to consider.
At the beginning of the workshop, parents/carers will be
advised of the study aims and the format of the workshop
and will be told that they are free to withdraw at any point
without giving reason. Parents/carers will be given oppor-
tunity to ask questions. Written informed consent will be
obtained by either a member of the study team or research
personnel included on the delegation log.
The workshop will be divided into three focus group
sessions (outcomes; study design; consent), each lasting
up to an hour. The research team will provide an over-
view of the study and the aims and objectives of the
workshop. Patient and Public Involvement (PPI) contrib-
utors will be invited to help facilitate the focus groups. A
topic guide will be developed for use in the workshop to
explore the following: identification and prioritisation of
outcomes; deferred consent (including decision-making
in the emergency setting); length and content of the par-
ticipant information sheets; and acceptability of the pro-
posed trial (including identification of potential barriers
for participation). Parents/carers’ advice will also be
sought on how best to recruit other parents/carers to
participate in a future Delphi consensus survey.
The first focus group session will concentrate on out-
come identification and prioritisation. A list of outcomes
and definitions will be prepared in advance to present to
parents/carers. Outcomes will be identified from pub-
lished bronchiolitis Cochrane systematic reviews and
NICE guidance and tabulated. Parents/carers will be
asked questions in relation to their experience of having
a child with bronchiolitis to identify important out-
comes. All outcomes identified by the parents/carers will
be recorded on flip-charts. Outcomes identified that are
not already on the prepared list will be included on the
list for prioritisation. The focus group will discuss each
outcome in the prepared list to clarify meaning, and
similar identified outcomes will be merged. Using Turn-
ingPoint software, parents/carers will be asked to priori-
tise outcomes using a Likert scale (1, Extremely
important to 5, Completely unimportant). Those out-
comes which are considered either extremely important
or important will be included in a prioritisation exercise
in the second focus group.
The second focus group will consider various features of
an RCT study design. Parents/carers will be given a dem-
onstration of different methods of providing oxygen ther-
apy and non-invasive respiratory support (HFNC and
nCPAP) to children with bronchiolitis using baby manne-
quins. Two different study design options will be dis-
cussed and explored: HFNC compared with standard care
and HFNC compared with nCPAP. Parents/carers will be
asked what they feel about the different interventions and
comparisons, how they would feel if their child was
involved in these studies and what outcomes they deem
important for each of the two study design options. Fol-
lowing the discussion of the two different study designs,
parents/carers will be asked which study design option
should be prioritised. The outcomes considered important
or extremely important from the previous focus group will
be written on Post-it Notes. Using a prioritisation grid
(see Additional file 3) designed specifically for this study,
parents/carers will be asked to prioritise nine of these out-
comes for the preferred study design [57]. Parents/carers
will be consulted on what they would consider to be a
minimally important difference for the primary outcome
measure on which to base a sample size calculation,
whenever feasible. For example, if parents/carers priori-
tised length of hospital stay, we would ask them what they
would consider to be an important reduction.
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The final focus group in the workshop will explore par-
ents/carers’ perceptions of prospective consent and re-
search without prior consent in relation to the two study
designs previously explored [58]. Parents/carers will be
provided with a draft participant information sheet for re-
search without prior consent for consideration. Finally,
parents/carers will be consulted over what is the best
method to use to approach other parents/carers with an
invitation to participate in a future Delphi survey.
Parent/carer telephone/Skype interviews Interim find-
ings from the workshop will be used to inform and de-
velop the telephone/Skype interview topic guide as part
of an iterative (reflective) approach to the research, al-
though the key topics and structure are likely to be simi-
lar to those of the workshop focus group topic guide.
Recruitment to telephone/Skype interviews will take
place at all seven study sites. If a parent/carer is re-
cruited prospectively, then written informed consent will
be obtained at the site. Parents/carers identified retro-
spectively who contact the study team will be included
on a register with their contact details. Approximately
one week prior to the interview, all parents/carers will
be sent a copy of the information sheet, consent form,
list of outcomes previously developed for use in the par-
ent workshop and copies of the NOVEMBR study (draft)
participant information sheet to consider. Parents/carers
will be contacted by the research team to ascertain
whether they still wish to participate in the interview, to
allow them to ask questions and to arrange a convenient
date and time for the interview. Parents/carers will be
able to select whether they would prefer a telephone or
Skype interview.
The researcher will begin the call by explaining the
aims of the study and provide further opportunity to ask
questions. Parents/carers will be advised that they are
free to withdraw from the study at any point without
giving reason. They will also be asked for permission to
use any data already collected. Data may include age,
gender, risk factors, severity of illness and the first part
of the postcode of the family home. Parents/carers, irre-
spective of being recruited prospectively or retrospect-
ively, will be guided through the consent form and
verbal consent will be obtained. This verbal consent
process will be digitally audio recorded and saved on a
separate file from the interview recording.
Interviews will be conducted with up to 15 parents/
carers based on similar studies [59] or until data satur-
ation is achieved (i.e. when no more new themes are
identified). All interviews will be conversational and
participant-centred to ensure that the interview content
reflects their own priorities and views on the proposed
trial design. It is anticipated that interviews will take no
longer than 60 min. To identify important outcomes,
parents/carers will be asked about their experience of
having a child with bronchiolitis and then be requested
to look at the outcome list. The researcher will go
through each outcome on the list to check understand-
ing and provide an explanation if required. Parents/
carers will be asked to identify which outcomes on the
list are important to them. Using a prioritisation grid,
parents/carers will be asked to rank the preidentified
outcomes in order of importance. Finally, parents/carers
will be asked to comment on the draft participant infor-
mation sheet for a potential future clinical trial.
HCP focus group workshops Recruitment of HCPs will
take place at all seven study sites. Information and invi-
tation to participate in the study will be disseminated via
health professional organisation global mailing lists or
through a brief presentation at appropriate clinical team
meetings. Clinical leads will be contacted to suggest an
HCP who may fit the inclusion criteria. An HCP may
also be approached directly by a member of the research
team and invited to participate. In addition, HCPs who
participated in two recent National Institute for Health
Research (NIHR)-funded bronchiolitis studies (UKCRN
10194 and UKCRN 10755) will be re-approached by
email. HCPs will be invited to contact the research team
to register an interest to take part in one of three work-
shops situated at different geographical locations around
England. The HCP will be asked to provide the following
information: contact details; profession type; grade; clin-
ical location; geographical area. A list of those HCPs
who register an interest in taking part in the study will
be used to purposively sample by profession, grade, clin-
ical speciality, hospital setting (secondary or tertiary)
and geographical location. A member of the research
team will contact those HCPs who have been selected to
explain key aspects of the study information, including
the purpose of the study, what is involved and the risks
and benefits of participation. Care will be taken to en-
sure that HCPs do not feel coerced to participate in the
study, and they will be advised that they can withdraw
from the study at any point without giving reason. If an
HCP withdraws, permission will be sought from the
HCP to use any data already collected.
As with the parent/carer workshop, there will be three
focus groups (outcomes; study design; consent) within
the workshop, each lasting approximately an hour. The
research team will use a workshop topic guide, similar
to the one used with the parents/carers, to explore iden-
tification and prioritisation of outcomes; consent (in-
cluding decision-making in the emergency setting) [58];
length and content of the participant information sheets;
and acceptability of the proposed trial (including identi-
fication of potential barriers for participation). Written
informed consent will be obtained at the beginning of
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the workshop from each HCP participant by either a
member of the research team or personnel included on
the delegation log.
In the first focus group the list of outcomes and defini-
tions prepared for the parent/carer focus group will be
provided for use. HCPs will be asked to reflect upon
their experience of managing children with bronchiolitis
to identify additional outcomes. All identified outcomes
will be recorded on flip-charts. The group will discuss
each outcome to clarify meaning, and similar outcomes
identified from the workshop discussions may be
merged. All additional outcomes identified that are not
already on the prepared list will be included for priori-
tisation. Using TurningPoint software, HCPs will be
asked to prioritise outcomes using a Likert scale (1, Ex-
tremely important, to 5, Completely unimportant).
Those outcomes which were considered either extremely
important or important will be recorded on Post-it
Notes and included in a prioritisation exercise in focus
group two.
Two different study design options will be discussed
and explored in focus group two: HFNC compared with
standard care and HFNC compared with nCPAP. HCPs
will be asked to consider and discuss topic areas related
to the design of the clinical trial, such as study interven-
tions and acceptability of a clinical trial of non-invasive
ventilation. HCPs will be asked which of the two trial
designs should be prioritised. Using a prioritisation grid
[57] and the outcomes recorded on Post-it Notes from
focus group one; HCPs will be asked to prioritise nine
outcomes, including a primary outcome. Similar to the
parent/carer focus group, HCPs will be consulted on
what should be considered as the minimally important
difference for the primary outcome. In the third focus
group HCPs will be asked to consider the use of pro-
spective consent and research without prior consent [58]
in relation to the two study designs previously discussed.
HCPs will be provided with a draft participant informa-
tion sheet for research without prior consent for
consideration.
Qualitative data analysis and storage All focus groups
and interviews will be audio recorded and transcribed
verbatim by an external transcription company. Tran-
scripts will be pseudo-anonymised. Audio files will be
deleted once transcribed; with the exception of the audio
recorded consent for parent/carer interviews. All study
data will be stored according to data protection require-
ments and local data governance policies. Identifiable
participant data will be kept in a file separate from the
anonymised participant data on a secure server on a
password protected NHS computer. All identifying de-
tails such as names, dates of births and hospitals will be
removed and replaced with pseudonyms. All participants
will be identified with a unique identifier. All recordings,
transcripts and documents will be coded with the unique
participant identifier to ensure anonymity. Electronic
versions of the transcripts will be stored on the main
server of a password protected computer.
Digital audio recordings of focus groups and inter-
views will be transcribed verbatim. Other data sources
derived from focus groups and interviews will include
lists of words and phrases written down by the partici-
pants and words and phrases recorded on flip charts;
field notes made by the researchers will also be analysed.
Transcripts and all other data sources will be examined
iteratively several times over the course of the analysis.
Synthesis of all types of data sources will be undertaken
using a constant comparative method [60]. Initial exam-
ination of the data will aim to provide an overview of
the data with general impressions recorded, including
key ideas, themes and concepts arising from the content.
A descriptive thematic analysis will then be undertaken
[61]. This process will involve manually coding the raw
data, then collapsing the coded data under broader
themes. Codes and themes will be inductively derived
from the data. As new codes emerge, they will be applied
iteratively to the whole data set in subsequent examina-
tions of the data sources until no new codes or themes
are identified. A descriptive account will be produced for
each theme. Finally, outcomes identified from transcripts
and other data sources will be grouped under appropri-
ate domains and sub-domains using the predefined con-
ceptual bronchiolitis conceptual framework. QRS NVivo
(version 10) software will be used to support the coding
and synthesis of data. Field notes will be used to support
the analysis through describing the environmental geog-
raphy, participant interaction, group dynamics, behav-
iour and non-verbal communication. Field notes will
also enable the researcher to reflect on the focus groups
and interviews and record any meaningful thoughts and
insights.
Delphi survey to prioritise outcomes to include in a COS
In the third and final stage, we will undertake a Delphi
survey to reach consensus over which outcome mea-
sures to include in a COS for trials in the management
of children with bronchiolitis. We will adopt this ap-
proach to ensure the anonymous opinions of important
stakeholders (parents/carers and HCPs) are obtained in
a way that gives equal influence to all who participate,
and avoids an individual participant being overtly influ-
enced by the opinions of other participants [62, 63].
We will review all outcomes identified from the sys-
tematic review and stakeholder consultation (workshops
and interviews) for inclusion in the Delphi survey. Out-
comes considered similar (for example, those that meas-
ure the same phenomenon) will be collapsed and
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merged. Each outcome will be categorised under the
relevant domains and sub-domains in the outcomes
framework defined a priori, as previously stated.
Stakeholders who meet the following eligibility criteria
will be invited to complete the Delphi survey:
1. Parents/carers of a child hospitalised between 2016
and 2018 (including ED attenders), aged 0–24 months,
with a clinical diagnosis of bronchiolitis defined as per
NICE Bronchiolitis Guidelines [56]
2. HCPs (nurses, doctors, physiotherapists) who have
at least 6- months experience in managing children
diagnosed with bronchiolitis.
We will also invite eligible stakeholders who have been
involved with earlier phases of the study to participate.
Parents/carers who do not speak English or whose child
has died during hospital admission will be excluded.
Sample and setting There is currently no standard
method to determine sample size for the Delphi survey.
A pragmatic decision to recruit up to 40 parents and up
to 300 HCPs was taken based on other studies [64, 65].
Efforts will be taken to maximise the response rate
across centres and stakeholder groups.
Eligible parents/carers who were approached to par-
ticipate in workshops or interviews will be asked to
complete a permission to contact form. This form will
include a box to be ticked to indicate interest in partici-
pation in the Delphi survey. In addition, we will invite
several UK hospitals to become participant identification
centres (PICs). A member of the research team at each
PIC will identify eligible parents and provide them with
the Delphi information sheet. The information sheet
outlines the Delphi survey process and provides instruc-
tions on how to contact a member of the study team for
more information. PICs will also be asked to display
posters advertising the Delphi survey in relevant clinical
areas. We intend to make links with a number of general
or respiratory-specific patient advocacy groups in order
to circulate the poster and the contact details for the re-
search team.
To identify eligible HCPs, the study team will send an
email advertising the Delphi survey to professional orga-
nisations for them to distribute to members via global
email address lists or associated social media sites. Pro-
fessional organisations will at least include the following:
NIHR Clinical Research Network: Children; General and
Adolescent Paediatric Research Collaborative - UK and
Ireland (GAPR-UKI); Acute Paediatric Emergency Medi-
cine (APEM); Royal College of Nursing Children’s and
Young Persons Forum. We will ask PICs to circulate
Delphi survey information to the relevant HCPs within
their organisation. In addition, clinicians who complete
the national survey of current practice will be asked to
provide their email address if they wish to be contacted
regarding participation in the Delphi survey.
All participants will be invited to pass on details of the
study to any of their own contacts who meet eligibility
requirements. Potential participants will be given details
of how to register when they contact the study team.
Screening questions will be included on the Delphi
registration page for potential participants to complete.
If they do not meet these criteria, then they will be un-
able to complete the registration process. Eligible partici-
pants will be included on a register and allocated a
unique identifier. We will use the unique identifier to
anonymise and store data and to track attrition rates be-
tween rounds. The following information will be col-
lected for each stakeholder group:
1. Parents/carers: When the respondent’s child was
hospitalised with a diagnosis of bronchiolitis
2. HCPs: Respondent’s clinical role; whether
respondent works in a secondary care, tertiary care
or ‘other’ setting; name of respondent’s employing
organisation; number of years post-professional
registration; grade.
A statement will be included on the Delphi registra-
tion page highlighting that completion of the question-
naire will be regarded as consent.
Delphi survey methods We will upload outcomes iden-
tified from the systematic review and stakeholder con-
sultation onto the web-based Delphi system (Delphi
Manager Application version 1.1). This system will facili-
tate management of the Delphi survey. A hyperlink to
access the survey will be embedded in an email along
with the study information sheet. The information sheet
will provide participants information on the NOVEMBR
study and the Delphi survey, notify participants that
their participation is voluntary and stress the importance
of completing all Delphi survey rounds. Furthermore, we
will inform participants that if they complete all Delphi
survey rounds they will be entered into a prize draw to
win an iPad and that HCPs will receive a certificate of
completion. The Delphi survey will be pilot tested prior
to distribution to determine any technical issues with
the software, clarity of wording, time taken to complete
the survey and ease of use, and the survey will be refined
as necessary. We will ask participants to complete each
round of the Delphi survey within four weeks following
receipt of the email. Participants will be reminded of this
at the start of each survey. A reminder email will be sent
out at the end of the first week to prompt completion of
the survey. Withdrawals will be classed as those partici-
pants who contact the NOVEMBR study team directly
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or write a comment in the survey comments box to indi-
cate they do not wish to participate in any more Delphi
survey rounds.
Delphi survey round one will contain:
1. A list of outcomes to be scored, ordered
alphabetically by domains. The list of outcomes will
include the option to display a more detailed plain
language description. The text will be reviewed by
the study team and parent representative.
2. An option for a participant to add any additional
outcomes and to provide a score for each outcome
added.
At the beginning of the survey, participants will be
asked the following key question:
What outcomes are most important in the
management of children with bronchiolitis?
Participants will be asked to score each of the outcomes
listed using the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) scale of 1–9
[66]. In the Delphi exercise the scale will be presented in
the format 1–9 with 1–3 labelled as 'not important', 4–6
labelled as 'important but not critical', 7–9 labelled as 'crit-
ical' and the choice 'unable to score' [66]. Participants will
be provided with an option to add additional outcomes
that they think are relevant together with a score for each
outcome added. Outcomes will be listed alphabetically to
avoid potential weighting caused by the order in which
they are displayed. Additional outcomes listed by partici-
pants will be reviewed and coded by members of the study
team to ensure they represent new outcomes. The SMG
will be consulted if there is uncertainty. For each outcome,
the number of participants who have scored the outcome
and the distribution of scores (as a percentage of those
who have scored each outcome) will be summarised based
on stakeholder group. All outcomes will be carried for-
ward to round two.
The number of participants in each stakeholder group
who respond to round one will be assessed following
round one closure. Results will be presented as:
 Total number of registrations
 Breakdown of respondents who have completed the
survey and their inclusion in the initial email
invitation
 Total number of respondents who completed the round
 Total number of respondents in each stakeholder
group
 Percentage of respondents compared to potential
respondents as identified from the information
provided by clinical leads
 Percentage of respondents from other sources (not
included in original email invitation)
If a low number of responders (less than 10) is ob-
served for one or more stakeholder groups, the Delphi
protocol for future rounds will be reviewed and revised.
Where there is only one stakeholder group with a small
number of respondents (potentially due to the sample
available from clinical teams), then consideration will be
given to grouping with another stakeholder group; e.g.
physiotherapists may be grouped along with nursing
staff. This will be done in consultation with the SMG to
ensure appropriateness of grouping. The proposed ap-
proach assumes sufficient numbers of stakeholders from
each group who respond. Continuation to round two
will be considered based on the response to round one.
Those who have not taken part in round one and not
provided a score will not be invited to participate in
round two.
In round two, participants will be shown their own
scores for each outcome as well as the scores given by
each stakeholder group using a bar chart displaying the
distribution of scores. Participants will then be asked to
re-score all outcomes and state whether they should be
included in a COS. Participants will be provided with
the option to explain any significant score changes.
Round two will be presented online. The total number
of participants invited to take part in round two will be
recorded. For each outcome, the number of participants
who have scored the outcome and the distribution of
scores will be summarised together with the number of
participants who have scored the outcome in all rounds.
Results of the stakeholder group response will be com-
pared to the whole group response, and the percentage
agreement used to determine the structure and focus of
the final consensus meeting. Each outcome will be clas-
sified as either ‘consensus in’, ‘consensus out’ or ‘no con-
sensus’ as described in Table 1 [66].
For consensus to have been reached that an outcome
should be included in the COS, there must be agreement
by a clear majority on the importance of the outcome
with only a small minority considering it to be not im-
portant at all. For consensus to have been reached that
an outcome should not be in the COS, there must be
agreement by a clear majority on the lack of importance
of the outcome with only a small minority considering it
to be important. Whilst the choice of thresholds is inev-
itably somewhat subjective, the definition of consensus a
priori should reduce the chance of consensus being de-
fined post hoc in such a way as to bias the results to-
wards the beliefs of the research team [48]. Once the
final analysis of the online Delphi survey has been con-
ducted, the results will be summarised, a report will be
written by the study researcher and recommendations
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for future research will be made based on the findings of
the study.
National survey of practice
To investigate current practice in the management of
children with a clinical diagnosis of bronchiolitis, a na-
tional survey of practice will be developed. The survey
will be pilot tested and circulated by the Liverpool Clin-
ical Trials Research Centre (CTRC) to UK hospitals and
paediatric research groups. The survey will be developed
using SurveyMonkey® software. Lead paediatricians for
each NHS trust will be sent an email inviting them to
complete the survey, which will be accessed via a hyper-
link embedded into the email. The survey will cover
topics such as current treatment, method of delivering
treatment, available facilities and staffing levels, level of
staff training and whether the survey participants believe
it would be feasible to run a randomised control trial of
non-invasive ventilation in children with bronchiolitis at
their hospital. Furthermore, there will be a request
within the survey for lead paediatricians to forward local
bronchiolitis guidance to establish variation in practice.
In addition to the survey, screening logs will be com-
pleted, for six weeks, over two bronchiolitis seasons at
five sites (until March 2018). The purpose of the screen-
ing logs is to collect admission data, which will include
age upon admission, length of patient stay, referral route,
risk factors, reason for admission, treatment, oxygen
therapy and patient outcome. The screening logs will
provide further information on current management of
children with bronchiolitis and the proportion of chil-
dren who require non-invasive ventilation. Once the sur-
vey and screening logs have been completed, they will be
returned to the CTRC, where the responses will be col-
lated and analysed by the study statistician.
Consensus meeting
The final phase of the study will be a face-to-face con-
sensus meeting. All participants involved with either
stakeholder consultation and/or Delphi will be invited to
attend. The final format of the consensus meeting will
be determined following review of the experiences of
previous similar projects [67]. This will include deciding
on the Chair and attendees, recruitment and consent,
list of outcomes to be presented for discussion and the
consensus methods. Results from the systematic review,
stakeholder consultation, Delphi survey and national
survey of practice will be presented. There will then be a
final discussion and vote on the trial design and bron-
chiolitis COS.
Discussion
This feasibility study protocol describes how we plan to
design a future clinical trial to investigate the efficacy of
non-invasive ventilatory support and the development of
a COS for children with bronchiolitis. The current pub-
lished literature demonstrates a real need for further
well-designed trials that include outcomes relevant to
important stakeholder groups. Furthermore, a bronchio-
litis COS would greatly improve measurement and
reporting of outcomes in future research. Therefore, this
study will contribute to the burgeoning evidence base in
this area and, one hopes, improve the future healthcare
of these children.
Proposed clinical trial
This feasibility study will enable us to make important
decisions regarding any future clinical trial such as
whether a trial is necessary, which interventions to pri-
oritise and which primary and secondary outcomes to
use. Furthermore, the screening log and national survey
of practice will help identify issues with capability and
capacity, such as variation in practice; availability of
equipment; and staffing issues and training require-
ments. If a trial is thought to be necessary, then the final
output of this study will be to develop a protocol for
such a trial with a view to seeking funding in the UK.
Core outcome set development
There is no COS for children with bronchiolitis. The
methodology we have described for COS development
adheres to the recently published Core Outcome
Set-STAndards for Development (COS-STAD) recom-
mendations, which describe three key domains import-
ant in the development of any COS: scope, stakeholder
involvement and consensus process [51, 68].
The scope of the COS includes children up to 24 months
old with a clinical diagnosis of bronchiolitis in a hospital set-
ting (standards 1, 2, 3 and 4) [51]. Moreover, we intend to in-
corporate both pharmacological and non-pharmacological
interventions. There are limitations concerning the scope.
Firstly, it is restricted to children residing in the UK in terms
Table 1 Consensus classification for all stakeholder groups
Consensus classification Description Definition
Consensus in Consensus that outcome should be included in the
core outcome set
70% or more participants scoring as 7–9 AND
< 15% participants scoring as 1–3 in each group
Consensus out Consensus that outcome should not be included in
the core outcomes set
< = 50% of participants scoring as 7-9 in each group
No consensus Uncertainty about importance of outcome Anything else
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of bronchiolitis definition and setting. This may preclude the
uptake of the COS internationally. Further evaluation in
countries outside the UK may be necessary to mitigate this
limitation. Secondly, the COS is limited to a hospital setting.
A large proportion of children with bronchiolitis are cur-
rently managed in the community. It may be necessary for
future studies to address this shortcoming. The presuppos-
ition is that a bronchiolitis COS will be primarily used for fu-
ture clinical research. However, other potential applications
for the bronchiolitis COS could include quality improve-
ments in clinical practice and guideline development.
Notably, we will involve and consult important stake-
holders throughout this study. This important contribu-
tion will help ensure that future research outputs, in
terms of the clinical trial and COS, will be both accept-
able and relevant to all major stakeholder groups. The
inclusion of HCPs and parents/carers meets the
COS-STAD recommendations (standards 6 and 7) for
developing a COS [51]. A limitation with respect to
stakeholder involvement is the lack of engagement with
industry partners as participants. These stakeholders
were not considered for inclusion because, at the time
the protocol for this study was developed, there were no
specific treatments for either bronchiolitis or the viruses
that cause bronchiolitis. This has recently changed; anti-
viral medications are undergoing early phase clinical tri-
als [69, 70].
The consensus process for identifying, including and
excluding outcomes has been clearly described a priori
in accordance with COS-STAD recommendations (stan-
dards 8, 9, 10 and 11) [51]. Stakeholders (parents/carers
and HCPs) will be fully involved in this process through
focus groups, interviews, a Delphi survey and a consen-
sus meeting (standard 8) [51]. We are using the GRADE
scale to score the list of outcomes for importance [66],
and consensus will be defined using the definition devel-
oped for the mOMEnt study [54] (standards 9 and 10)
[51]. HCP and parent representatives will be on the
SMG to review all outcomes for ambiguity of language
(standard 11).
Finally, future research for the definitive bronchiolitis
COS will include exploring how best to measure each of
the outcomes included.
3.3. Trial status
At the time of manuscript submission, the NOVEMBR
feasibility study was still open to recruitment. The
NOVEMBR study opened for recruitment on 12/2/2016
(Protocol v1.0 Date: 19.10.15), and recruitment was
completed by 14/6/2018.
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